Overview

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Centers for Disease Control and Prevention
National Eye Institute (NEI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
Treatments:
Acarbose
Amlodipine
Antihypertensive Agents
Benazepril
Candesartan
Candesartan cilexetil
Carvedilol
Chlorthalidone
Diltiazem
Felodipine
Fenofibrate
Furosemide
Glimepiride
Hydralazine
Hydrochlorothiazide
Hydrochlorothiazide-triamterene
Hydrochlorothiazide, lisinopril drug combination
Hypoglycemic Agents
Insulin
Insulin Aspart
Insulin Detemir
Insulin Glargine
Insulin, Globin Zinc
Lisinopril
Metformin
Metoprolol
Pioglitazone
Repaglinide
Reserpine
Rosiglitazone
Simvastatin
Terazosin
Triamterene
Valsartan